• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[未分化和去分化肾细胞癌:基于最新进展的形态分子学特征及鉴别诊断]

[Undifferentiated and dedifferentiated renal cell carcinomas : Morphomolecular aspects and differential diagnosis in light of recent developments].

作者信息

Agaimy Abbas, Hartmann Arndt

机构信息

Institut für Pathologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstraße 8-10, 91054, Erlangen, Deutschland.

出版信息

Pathologie (Heidelb). 2025 Feb;46(1):40-47. doi: 10.1007/s00292-024-01409-3. Epub 2024 Dec 30.

DOI:10.1007/s00292-024-01409-3
PMID:39738515
Abstract

Histological subtyping of diverse renal cell carcinomas (RCCs) has seen significant changes during the last two decades. This resulted in the introduction of several new phenotypically and genetically defined entities, many which are also listed in the current WHO classification. Some of these well-defined entities may, under certain circumstances, undergo a process of dedifferentiation resulting in loss of their phenotypic and immunohistochemical features, hence adopting a non-descript anaplastic morphology. Accordingly, the original entity-defining tumor clone might be either totally overgrown and lost or just be missed by sampling the tumor. This final common pathway of dedifferentiation results in several oncological disadvantages and prevents a histology-tailored approach to systemic therapy. In addition, the possibility of inherited cancer as in the case of SDH- and FH-deficient RCC would be easily overlooked if the exact subtyping is not possible. This overview article illuminates the main RCC subtypes that may undergo dedifferentiation and their differential diagnostic approach.

摘要

在过去二十年中,各种肾细胞癌(RCC)的组织学亚型分类发生了显著变化。这导致引入了几个新的表型和基因定义的实体,其中许多也列在当前的世界卫生组织分类中。在某些情况下,这些定义明确的实体中的一些可能会经历去分化过程,导致其表型和免疫组化特征丧失,从而呈现出无特征性的间变形态。因此,最初定义实体的肿瘤克隆可能会完全过度生长并消失,或者在对肿瘤进行取样时被遗漏。这种去分化的最终共同途径导致了几个肿瘤学上的不利因素,并阻碍了针对全身治疗的组织学定制方法。此外,如果无法进行准确的亚型分类,像SDH和FH缺陷型RCC那样的遗传性癌症的可能性很容易被忽视。这篇综述文章阐明了可能发生去分化的主要RCC亚型及其鉴别诊断方法。

相似文献

1
[Undifferentiated and dedifferentiated renal cell carcinomas : Morphomolecular aspects and differential diagnosis in light of recent developments].[未分化和去分化肾细胞癌:基于最新进展的形态分子学特征及鉴别诊断]
Pathologie (Heidelb). 2025 Feb;46(1):40-47. doi: 10.1007/s00292-024-01409-3. Epub 2024 Dec 30.
2
Undifferentiated and dedifferentiated urological carcinomas: lessons learned from the recent developments.未分化和去分化泌尿上皮性癌:来自最新进展的启示。
Semin Diagn Pathol. 2021 Nov;38(6):152-162. doi: 10.1053/j.semdp.2021.09.004. Epub 2021 Sep 20.
3
What Is New in Pathologic Diagnosis and Classification of the Common Renal Cell Neoplasms?常见肾细胞肿瘤的病理诊断与分类有哪些新进展?
Surg Pathol Clin. 2025 Mar;18(1):133-155. doi: 10.1016/j.path.2024.08.011. Epub 2024 Oct 9.
4
[2022 WHO classification of renal cell carcinomas: Focus on papillary renal cell carcinoma].[2022年世界卫生组织肾细胞癌分类:聚焦于乳头状肾细胞癌]
Ann Pathol. 2024 Sep;44(5):314-322. doi: 10.1016/j.annpat.2024.04.018. Epub 2024 May 9.
5
Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.肾髓质癌、集合管癌和富马酸水合酶缺陷型肾细胞癌之间形态差异的再评估。
Am J Surg Pathol. 2018 Mar;42(3):279-292. doi: 10.1097/PAS.0000000000001000.
6
Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma: Analysis of 32 Cases Indicating a Distinctive Common Pathway of Dedifferentiation Frequently Associated With SWI/SNF Complex Deficiency.肾细胞癌中的横纹肌样和未分化表型:32例分析表明存在一种独特的去分化共同途径,常与SWI/SNF复合物缺陷相关。
Am J Surg Pathol. 2017 Feb;41(2):253-262. doi: 10.1097/PAS.0000000000000787.
7
Re-evaluation of 33 'unclassified' eosinophilic renal cell carcinomas in young patients.重新评估 33 例年轻患者的“未分类”嗜酸性肾细胞癌。
Histopathology. 2018 Mar;72(4):588-600. doi: 10.1111/his.13395. Epub 2017 Dec 4.
8
[Molecularly defined renal cell carcinomas].[分子定义的肾细胞癌]
Pathologie (Heidelb). 2025 Feb;46(1):5-12. doi: 10.1007/s00292-024-01408-4. Epub 2025 Jan 27.
9
Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features.具有混合组织学特征的肾细胞癌的当代诊断与分类方法。
Chin J Cancer. 2013 Jun;32(6):303-11. doi: 10.5732/cjc.012.10136. Epub 2012 Dec 7.
10
New insights in the new WHO classification of adult renal tumors.世界卫生组织成人肾肿瘤新分类中的新见解。
Cesk Patol. 2022 Fall;67(4):187-191.

本文引用的文献

1
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).纳武利尤单抗在转移性肾细胞癌患者中酪氨酸激酶抑制剂诱导后的维持治疗:德国癌症学会多学科肾癌工作组(NIVOSWITCH;AIO-NZK-0116ass)的一项随机临床试验。
Eur Urol. 2023 Dec;84(6):571-578. doi: 10.1016/j.eururo.2023.09.004. Epub 2023 Sep 26.
2
What's new in the WHO 2022 classification of kidney tumours?世界卫生组织 2022 年版肾脏肿瘤分类有哪些新内容?
Pathologica. 2022 Feb;115(1):8-22. doi: 10.32074/1591-951X-818. Epub 2023 Jan 16.
3
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of View.
欧洲泌尿外科协会肾细胞癌指南小组关于《2022年世界卫生组织肾脏肿瘤分类》的更新:泌尿外科医生的观点。
Eur Urol. 2023 Feb;83(2):97-100. doi: 10.1016/j.eururo.2022.11.001. Epub 2022 Nov 23.
4
Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group.转移性肾细胞癌 (mRCC) 的系统治疗:德国跨学科 RCC 指南小组的循证推荐。
World J Urol. 2022 Oct;40(10):2381-2386. doi: 10.1007/s00345-022-04015-1. Epub 2022 May 13.
5
Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients.扩展琥珀酸脱氢酶缺陷型肾细胞癌的临床病理谱,重点关注变异形态:59 例患者 62 例新肿瘤的研究。
Mod Pathol. 2022 Jun;35(6):836-849. doi: 10.1038/s41379-021-00998-1. Epub 2021 Dec 23.
6
Pleomorphic (giant cell) carcinoma revisited: A historical perspective and conceptual reappraisal.多形性(巨细胞)癌再探:历史视角与概念再评价。
Semin Diagn Pathol. 2021 Nov;38(6):187-192. doi: 10.1053/j.semdp.2021.09.003. Epub 2021 Sep 20.
7
Undifferentiated and dedifferentiated urological carcinomas: lessons learned from the recent developments.未分化和去分化泌尿上皮性癌:来自最新进展的启示。
Semin Diagn Pathol. 2021 Nov;38(6):152-162. doi: 10.1053/j.semdp.2021.09.004. Epub 2021 Sep 20.
8
New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.现有世卫组织实体的新发展和不断发展的分子概念:泌尿生殖系统病理学学会 (GUPS) 关于肾肿瘤的更新。
Mod Pathol. 2021 Jul;34(7):1392-1424. doi: 10.1038/s41379-021-00779-w. Epub 2021 Mar 4.
9
Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.新型、新兴和暂定的肾脏实体:泌尿生殖系统病理学学会(GUPS)关于肾脏肿瘤的更新。
Mod Pathol. 2021 Jun;34(6):1167-1184. doi: 10.1038/s41379-021-00737-6. Epub 2021 Feb 1.
10
ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217.间变性淋巴瘤激酶重排肾细胞癌 (ALK-RCC):十二例病例的多机构研究,鉴定出新的伙伴基因 CLIP1、KIF5B 和 KIAA1217。
Mod Pathol. 2020 Dec;33(12):2564-2579. doi: 10.1038/s41379-020-0578-0. Epub 2020 May 28.